Full Text View
Tabular View
Study Results
Related Studies
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
This study has been completed.
Study NCT00082017   Information provided by National Institutes of Health Clinical Center (CC)

First Received on April 28, 2004.   Last Updated on July 26, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Large-Cell, Ki-1
Lymphoma, T-Cell
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Large-Cell, Anaplastic
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
UCN-01 (7-hydroxystaurosporine)
Additional drug interventions recognized in this trial
7-hydroxystaurosporine
Staurosporine
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services